scispace - formally typeset
R

Robert Lischke

Researcher at First Faculty of Medicine, Charles University in Prague

Publications -  97
Citations -  879

Robert Lischke is an academic researcher from First Faculty of Medicine, Charles University in Prague. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 12, co-authored 63 publications receiving 592 citations. Previous affiliations of Robert Lischke include Charles University in Prague.

Papers
More filters
Journal ArticleDOI

Predictors of prolonged air leak following pulmonary lobectomy.

TL;DR: It is concluded that COPD increases the risk of an air leak persisting for longer than 7 days and significantly prolongs the length of hospitalization.
Journal ArticleDOI

Novel biodegradable stents in the treatment of bronchial stenosis after lung transplantation

TL;DR: This small pilot study shows that BD stents are a safe, effective and reliable alternative to classical metallic stents in patients with anastomotic stenosis after lung transplantation, and may avoid the need for permanent stenting.
Journal ArticleDOI

Immunogenicity of BNT162b2 mRNA COVID-19 vaccine and SARS-CoV-2 infection in lung transplant recipients.

TL;DR: In this article, the authors compared the antibody response after the first and second doses of the BNT162b2 mRNA COVID-19 vaccine (Pfizer-BioNTech) with the response after natural SARS-CoV-2 infection in lung transplant recipients.
Journal ArticleDOI

Anastomotic leak and stricture after hand-sewn versus linear-stapled intrathoracic oesophagogastric anastomosis: single-centre analysis of 415 oesophagectomies

TL;DR: The non-randomized study showed that side-to-side LS technique is the preferred method of intrathoracic oesophagogastric anastomosis due to a decreased overallAnastomotic leak rate and anastsomotic stricture formation compared with HS technique.
Journal ArticleDOI

The TRAIL in the Treatment of Human Cancer: An Update on Clinical Trials.

TL;DR: A review of the most promising TRAIL-based clinical trials and their therapeutic strategies is presented in this article, where the current status of all TRAILbased monotherapies and combination therapies that have reached phase II and phase III clinical trials in humans.